Assessing response to anti-CD20 therapy by genotyping C1q components
US7723036B2 · kind B2 · utility
11Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2006 |
| Grant date | May 25, 2010 |
| Priority date | — |
| Expiry date | Apr 11, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention encompasses methods for predicting metastasis in cancer by assessing the structure of the complement protein C1qA. The methods may encompass examining either protein or nucleic acids, and may further include making treatment decisions based on the predictive methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.